本帖最后由 老马 于 2013-3-13 13:43 编辑 2 X5 \; O: M; z- G
~8 m# \( V. \2 L3 _
健择（吉西他滨）+顺铂+阿瓦斯汀
& T5 w8 g5 K3 u: l9 @ Gemzar +Cisplatin + Avastin
5 N9 g+ A& d( y4 y% nhttp://annonc.oxfordjournals.org/content/21/9/1804.full
# |4 s+ H" J+ p1 m8 H' sOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) ' ]+ j; y% @, X; Q# a. V6 r& r1 d
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
) A7 U) q, J3 {1 g1 \' PResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
- ~5 p. v* R* G# \( ?( Y
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 818)
- T6 e, W) p8 U华为网盘附件：
: \9 p5 G# W' _0 x$ Q( v: N7 X【华为网盘】ava.JPG
" u5 o" W( M) N. L% Q+ I. E4 v8 p! U |
显身卡
